DxNA

About:

DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.

Website: http://www.dxna.com/

Description:

DxNA LLC develops and manufactures high value molecular diagnostic instruments/platforms and tests with an emphasis in the area of infectious diseases. The company’s primary focus is on bringing the benefits of molecular testing to underserved community hospitals and clinics so that diagnostic information is more readily and quickly available. Using this information in a timelier manner has been shown to impact clinical decision making, improve patient outcomes and lower treatment costs. To make molecular testing available to more patients, the company has developed the GeneSTAT® System™ as its first instrument system. This novel, patented and highly portable instrument is combined with a proprietary test cartridge to provide easy to use, rapid and affordable Real-Time PCR molecular testing capabilities that are ideal for low to moderate throughput locations. Examples of target markets for the GeneSTAT System include small to mid-sized community hospitals, clinics, and rural healthcare facilities where high cost & high volume instruments requiring specially trained laboratory technicians are not viable.

Total Funding Amount:

$6.62M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Saint George, Utah, United States

Founded Date:

2005-01-01

Contact Email:

Info(AT)dxna.com

Founders:

Bill Bickmore

Number of Employees:

11-50

Last Funding Date:

2015-12-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai